

Cipla partners with CSIR-CDRI to advance ophthalmic anti-fungal treatment development

16 February 2024 | News

Cipla will scale up the product and conduct the required studies

Mumbai-based pharmaceutical firm Cipla has entered into a collaborative research agreement with Lucknow-based CSIR-Central Drug Research Institute (CSIR-CDRI), a constituent laboratory of the Council of Scientific and Industrial Research (CSIR), Government of India, to jointly develop a novel ophthalmic formulation for fungal keratitis. The collaboration aims to leverage the combined expertise and resources of both organisations to develop a safe and efficacious drug for fungal keratitis.

Globally, approximately 1.2 million cases of fungal keratitis are reported every year with tropical countries recording a higher incidence. Fungal keratitis often occurs following ocular trauma and exposure to fungal pathogens from organic matter, thus putting agricultural workers at greater risk. Other risk factors include the use of local steroid eye drops, injury, poor personal hygiene, and regular contact lens wear. Left untreated, the condition can result in corneal destruction, leading to a profound loss of vision. Existing therapies have limitations, such as the need for prolonged and frequent use of drugs, and emerging drug resistance.

CSIR-CDRI has developed a prototype formulation for an anti-fungal drug to optimise its delivery in the eye. In preclinical studies, this formulation supports faster resolution of the infection. Cipla will scale up the product, conduct the required studies and seek regulatory approvals for commercialisation, ensuring accessibility for those in need.

Welcoming this partnership, Dr Radha Rangarajan, Director CSIR-CDRI said, “Our research focuses on finding innovative, cost-effective solutions for India’s unmet clinical needs. CDRI scientists have developed a unique ophthalmic formulation of the anti-fungal drug. This in turn is expected to accelerate cure and lead to better outcomes. Our collaboration with Cipla will enable the translation of the research into a drug product, with the potential to reduce the burden of disease.”